Title

New directions in the treatment of anxiety disorders

UMMS Affiliation

Department of Psychiatry

Publication Date

4-2000

Document Type

Article

Subjects

Anxiety Disorders

Disciplines

Behavioral Disciplines and Activities | Mental and Social Health | Pharmaceutics and Drug Design | Psychiatry | Psychiatry and Psychology

Abstract

Anxiety disorders play a prominent role in general medical and psychiatric practice, and their lack of recognition leads to significant morbidity. A major thrust of recent patent activity builds on clinical successes provided by serotonergic and GABA-ergic agents. A new understanding of the molecular basis for GABAA receptor subtype selectivity presents new possibilities for designing drugs that are highly specific for subpopulations of this receptor family. Despite a lack of clinical experience with less well-known neuropeptide agents, corticotrophin-releasing hormone (CRH) antagonists appear promising. This paper reviews the most prevalent anxiety disorders, their pharmacological treatments and describes trends in therapeutic patent activity since 1997.

Source

Bain EE, Candilis P. “New directions in the treatment of anxiety disorders.” Expert Opinion on Therapeutic Patents, 10(4): 389-402, 2000.

Journal/Book/Conference Title

Expert Opinion on Therapeutic Patents

Share

COinS